Biom’up present at the 8 th Strategic Council of Health Industries hosted by France’s Prime Minister

 Significant growth of the number of U.S. hospitals undergoing a medical-economic
evaluation of HEMOBLASTTM Bellows
 A strengthened sales force in the United States
Saint-Priest (France), July 25, 2018, 8:00 a.m. (CET) – Biom’up (the “Company”), specialist of surgical
hemostasis, today announces having been selected by France’s Prime Minister to be one of the eleven
young innovative companies, showcase of the French know-how, gathered at the Hôtel de Matignon
(France’s Prime Minister’s residence) on July 10, 2018 for the 8th Strategic Council of Health Industries
(CSIS) to concretely illustrate the dynamism of the French ecosystem for innovation.
Etienne Binant, Chief Executive Officer, commented: “While it is an honor that Biom’up was selected to
attend the Strategic Council of Health Industries, it also is the recognition of the worth and talent of our
teams that made it possible for our flagship product, HEMOBLASTTM Bellows, to be ranked as the world’s
leader in hemostatic products. I warmly thank our teams for their involvement. This Strategic Council of
Health Industries is an opportunity to praise Biom’up’s international journey, particularly our implantation in
the US market, where the first deliveries of HEMOBLASTTM Bellows were made at the beginning of July.”
Biom’up also announces that HEMOBLAST Bellows is now undergoing a medico-economic evaluation (via
Value Analysis Committees) at more than 95 hospitals throughout North America, versus 75 at the beginning
of the month. This growth occurs while the very first commercial delivery of HEMOBLAST Bellows to a firstclass
hospital in the southern United States was just completed.
Finally, Biom’up announces that its sales network in charge of selling HEMOBLAST Bellows in the United
States continues to grow, allowing the Company to further extend its geographical coverage in North
America. This is now a strong network of 135 members, bringing together seasoned senior executives and
a strong national network of independent, specialized sales representatives.
These promising elements demonstrate the interest of North American surgeons for our first-class
innovative product resulting from French research and whose commercial launch in the United States is
planned in the near future. With a cash position of €44.1 million as of June 30, 2018, the Company believes
to be able to meet the short and medium term investments required for this successful commercial launch.
Press release
2
Contacts
Biom’up
Chief Financial Officer
Jean-Yves Quentel
investisseurs@biomup.com
+33 4 86 57 36 10
NewCap
EU Investor Relations
Tristan Roquet Montégon
biomup@newcap.eu
+33 1 44 71 00 16
LifeSci Advisors
US Investor Relations
Hans Herklots
hherklots@lifesciadvisors.com
+41 79 598 7149
About HEMOBLAST
Biom’up obtained FDA approval for HEMOBLAST Bellows in December 2017. The expedited approval
arrived 7 months ahead of original plan, and led to a focus on industrial activities, as well as the recruitment
of sales and marketing teams in the U.S. to prepare the mid-2018 commercial roll-out of our lead product in
Europe and the U.S.
HEMOBLAST Bellows is an advanced hemostatic product to control bleeding in a broad range of surgical
procedures, such as cardiac surgery, general surgery, and orthopedic surgery. Biom’up conducted a
successful clinical trial in 412 patients admitted to cardio-thoracic, abdominal or orthopedic (lower limb)
surgeries, which met all of its primary and secondary endpoints. Given the compelling preliminary results
(93% effectiveness at 6 minutes, compared with 74% for the control arm), the Independent Data Monitoring
Committee (IDMC) unanimously recommended to stop the study after an interim analysis of the data, which
allowed the company to accelerate the submission of its filing for premarket approval (PMA) to US regulatory
authorities in June 2017. On July 12, 2018 Biom’up received the CE Mark for its Laparoscopic Applicator
HEMOBLAST Bellows designed to deliver the HEMOBLAST Bellows powder in minimally-invasive
procedures. The Company can thus be positioned on a new market segment of approximately 500,000
surgeries per year in Europe. On July 2, 2018, the Company also submitted an additional application to the
FDA for approval of HEMOBLAST Bellows for all laparoscopic surgical procedures in the United States.
About Biom’up
Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom’up designs hemostatic
products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties
(spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Its flagship
product, HEMOBLAST Bellows, is a unique hemostatic solution, ready to use (no preparation time needed,
no need to mix, no heat required), usable once or several times during the surgery and offering unique
efficacy features. Developed by a world-renowned scientific team, HEMOBLAST Bellows has obtained
positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412
patients in the United States. HEMOBLAST Bellows obtained its CE Mark in December 2016, and its PMA
(Pre-Market Approval) application was granted by the FDA (Food & Drug Administration) in December 2017
with a view to the commercial launch in the United States in the summer of 2018. Since its creation, Biom’up
has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV,
Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the Company’s managers, who have
invested €2 million in equity. Biom’up successfully completed its IPO on Euronext Paris, raising €42.5 million
in October 2017. In addition, the Company concluded a €16 million capital increase by means of a public
offering without preferential subscription rights in February 2018 and in April 2018, concluded a €25 million
bond with Athyrium Opportunities III Acquisition LP, a US fund specializing in innovative companies in the
healthcare sector